Where Are The Usual Suspects?
You may also be interested in...
With the loss of exclusivity for its blockbuster heart drug, Diovan, coming in September, management focused on the company’s long-term prospects during a fourth quarter financial update.
Rigorous planning and a multidisciplinary team including database experts and healthcare specialists with local knowledge are vital to effective real-world evidence, white paper shows.
The latest submission and expedited review program news and highlights from our US FDA Performance Tracker.